Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01330030 · ClinicalTrials.gov registry record · Phase 2
Selegiline Patch for Treatment of Nicotine Dependence
A Phase 2 study of Tobacco Use Disorder, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
- 1
- Study location
NCT01330030: Completed Phase 2 study of Tobacco Use Disorder, sponsored by Stanford University.
NCT01330030 is a Phase 2 study of Tobacco Use Disorder that has completed, run by Stanford University. The registered enrollment target is 243 participants, roughly in line with the 236-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01330030, a Phase 2 study of Tobacco Use Disorder, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
- 1
- Study location
Study Summary
Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.
Primary Outcome
expired-air carbon monoxide confirmed smoking abstinence at 52 weeks
Conditions Studied
Interventions
- DRUG Selegiline
- OTHER matching placebo
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2005-07 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
What the finished NCT01330030 record still lists
NCT01330030 is an interventional study that assigns participants to a tested intervention. The registered 243 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 236-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target.
The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Selegiline is the first listed.
NCT01330030 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01330030 about?
NCT01330030 is a clinical study titled "Selegiline Patch for Treatment of Nicotine Dependence". Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.
What is the current status of trial NCT01330030?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2005-07. Estimated completion is 2011-07.
What conditions does trial NCT01330030 study?
This clinical trial studies the following conditions: Tobacco Use Disorder.
What interventions are being tested in trial NCT01330030?
The interventions under investigation include: Selegiline (DRUG), matching placebo (OTHER).
Who is sponsoring clinical trial NCT01330030?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01330030 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01330030's enrollment target sits among peer trials
243 17th of 70 higher than 54 of 70 other Tobacco Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RECRUITING · Phase 2
-
Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity
RECRUITING · Phase 2
-
Cannabidiol for Reducing Cigarette Use
RECRUITING · Phase 2
-
An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction
RECRUITING · Phase 2
-
Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06253871 · 243 participants · Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NCT06289491 · 243 participants · NA
A Trial of Hydrus Microstent Versus Goniotomy
- NCT06536296 · 243 participants · NA
The Impact of Music Medicine on Preterm Brain Development and Behavior
- NCT06907615 · 243 participants · Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia